How functional genomics informs nano-drug design for precision cancer medicine

A.H. Stegh
Robert H. Lurie Cancer Center, Northwestern University, US

Keywords: nano drug, design, cancer, genomics


High-throughput characterization and functional interrogation of cancer genomes has unraveled a complex landscape of genetic and epigenetic modifications, and has initiated the implementation of personalized cancer medicine into clinical practice. The sheer complexity of genomic information, and the difficulty to concomitantly modulate the action of multiple 'undruggable' targets, however, pose significant challenges to drug development. Here, I provide an overview of target gene identification in my laboratory, which has to led to the identification of critical cancer genes, in particular those implicated in the genesis and progression of malignant glioma. I will discuss how these findings can inform the design of RNA interference (RNAi)-based nanotechnological platforms, in particular siRNA and microRNA-based spherical nucleic acids, to overcome some of the most critical barriers to clinical progress, foremost the targeting of the undruggable oncogenome, and to enable precision (nano)drug design.